ENT 102

Drug Profile

ENT 102

Latest Information Update: 28 Jan 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Entropin (CEASED)
  • Class Anaesthetics; Analgesics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 28 Jan 2003 Discontinued - Preclinical for Pain in USA (Injection)
  • 18 Oct 2002 Entropin has filed a US patent application for the proprietary manufacturing process for ENT 102
  • 04 Oct 2002 Preclinical trials in Pain in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top